Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is an investigational autologous cell therapy developed by Al-Azhar University for the treatment of non-obstructive azoospermia (NOA). The therapy involves harvesting mesenchymal stem cells (MSCs) from a patient's own bone marrow, culturing them under Good Manufacturing Practice (GMP) conditions using autologous serum, and then transplanting them into the testicular tissue via intratesticular injection (specifically into the rete testis). The therapeutic goal is to restore spermatogenesis within the seminiferous tubules by activating or enhancing the resident spermatogonial stem cells, potentially leading to the production of motile sperm in patients who previously lacked them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells (Al-Azhar University).